Detection of furosemide, sibutramine, and/or fluoxetine adulteration in “all natural” weight loss consumer products at an international mail facility satellite laboratory using handheld/portable rapid screening instruments
A total of 97 consumer products claiming to be "all natural" or providing label graphics indicating potential weight-loss effects, were examined by a US Food and Drug Administration (FDA) National Forensic Chemistry Center (NFCC) International Mail Facility (IMF) satellite laboratory. All products were examined using a toolkit consisting of a handheld Raman spectrometer, portable Fourier-transform infrared (FT-IR) spectrometer, portable ambient ionization direct analysis in real-time mass spectrometer (DART-MS), and/or portable gas chromatography-mass spectrometry (GC-MS) instrument. Conclusive results were achieved for 89 out of 97 products using the satellite laboratory toolkit only. The remaining eight products were sent to the NFCC full-service laboratory for additional analysis using liquid chromatography with mass spectrometry (LC-MS). All 97 products were found to be adulterated with active pharmaceutical ingredients (APIs), with each containing at least two of the following drugs: furosemide, sibutramine, and/or fluoxetine. Furosemide and fluoxetine are only available with a prescription and sibutramine is a Schedule IV controlled substance. Furthermore, sibutramine, fluoxetine, and furosemide are all under the scope of section 801(u) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and therefore have been identified by FDA as a significant public health risk. Overall, the results of this study helped prevent over 24,000 adulterated consumer product capsules from reaching unsuspecting American consumers during a two-year timeframe.
Authors
- Lisa Lorenz (ORCID: https://orcid.org/0000-0002-0493-720X)
- Teneka L Jean-Louis (ORCID: https://orcid.org/0000-0003-2470-7724)
- Melissa E. Collins
- Caroline Machal Kelley
- Adam C. Lanzarotta (ORCID: https://orcid.org/0000-0002-9292-6403)
- Michael D. Thatcher (ORCID: https://orcid.org/0000-0002-3447-1383)
- Marie Marseille
- Sara E. Kern (ORCID: https://orcid.org/0000-0002-1980-6763)
- Megan E. Sterling
- Pan Jingjing
- Anvi Patel
- Christina Fernández
- Brian L. Boyd
- Joseph Carver (ORCID: https://orcid.org/0000-0002-6434-9522)
- Hannah LaRoy (ORCID: https://orcid.org/0009-0005-1653-452X)
- Allison Reimer
- Daurice J. McClain
- Jerae D. Byrd
- Muhammad Altaf
- Joan Cantellops Figueroa
- Cierra D. Bell
Institutions
- United States Food and Drug Administration (US)
Publication Details
- Journal
- Journal of Forensic Sciences
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1111/1556-4029.70482
- Primary Topic
- Pharmaceutical Quality and Counterfeiting
- Type
- article
- Field-Weighted Citation Impact
- 0.00